No Empty Shelves: Diabetes Supplies,
There When Needed - a partnership with PATH

Since 2014, Novo Nordisk and PATH have collaborated on the No Empty Shelves partnership project. The aim has been to address the barriers to access to affordable essential medicines and technologies (EMTs) for diabetes in low- and middle-income countries (LMICs).?



  1. Strengthen the global evidence base on availability of affordable essential medicines and technologies for diabetes in LMICs.
  2. Raise awareness of major barriers to availability of affordable diabetes EMTs.?
  3. Build a network of key stakeholders committed to taking action to increase the availability of affordable EMTs for diabetes and other NCDs.

The work of No Empty Shelves has been guided by a Technical Advisory Committee, comprised of the global health and development experts.?



The findings of No Empty Shelves clearly confirm that technologies – blood glucose monitoring (BGM) and syringes – and not insulin are the least affordable amongst the EMTs surveyed. Availability is very low in the public sectors, rural areas, and lower levels of care. The causes are various - from procurement issues that can impact supply to taxes and unregulated mark-ups that drive up costs.1



  • A comprehensive and peer-reviewed list of 22 EMTs necessary to diagnose and treat diabetes and its common comorbidities
  • A global landscape report?“Diabetes Supplies: Are they there when needed?”?published by PATH in 2015.?
  • Two comprehensive country assessments of the supply chain, availability and affordability of said medicines and products in Kenya and Senegal – manuscripts pending approval for publishing in peer-reviewed journal
  • A global?Call to Action?calling for access, availability, and affordability of essential medicines and technologies for noncommunicable diseases.??
  • The groundwork for establishing a cross-disciplinary coalition to increase access to essential medicines and technologies for NCDs.?The result of this groundwork is the global Coalition for Access to NCD Medicines and Products, launched in September 2017 in New York, and of which Novo Nordisk is a founding member.

See more about PATH and our corporate partnership?here



1. PATH. Diabetes Supplies: Are they there when needed? Seattle: PATH; 2015

More reading

List of essential medicines and technologies for diabetes

What does diabetes cost? Case from Kenya

Barriers to affordability and availability